August 27-29, 2020
Virtual event
ImmunoScape and Gilead Sciences recently presented findings at the Digital International Liver Congress 2020 that demonstrated the feasibility of simultaneously identifying and deeply characterizing rare HBV-specific T cells in heterogeneous HBV patient cohorts to facilitate the development of more effective therapeutic strategies for hepatitis B virus (HBV) infection.